Immuneering Q3 EPS $(0.47) Up From $(0.89) YoY
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.47) per share. This is a 47.19 percent increase over losses of $(0.89) per share from the same period last year.
Immuneering Reports Compelling Preclinical Data On IMM-1-104 At AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Immuneering Corporation (NASDAQ:IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today
Immuneering Reports Will Present Preclinical Data Across Several Poster Presentations At AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oct. 7-10
Preclinical Data Demonstrates Broad Antitumor Activity of IMM-1-104 Across RAS and RAF Mutant Tumors and Highlights Mechanistic Aspects of its Dual MEK Inhibition
Company to Host Key Opinion Leader Event on October 12,
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 20)
48 Biggest Movers From Yesterday
Gainers
Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients.
